Actualités
Date de dernière mise à jour : 21/01/2021
Epidémiologie
Worldwide burden of cancer attributable to HPV by site, country and HPV type
Int. J. Cancer: 141, 664–670 (2017) VC 2017 International Agency for Research on Cancer (IARC/WHO); licensed by UICC
Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial
Gynecol Oncol (2015)
Dépistage du cancer du col
Dépistage primaire de l’infecion HPV : Place dans l’organisation du dépistage du cancer du col utérin
GYNÉCOLOGIE OBSTÉTRIQUE PRATIQUE N° 329 • Novembre 2020
Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types
Int. J. Cancer: 144, 1975–1982 (2019)
Évaluation de la recherche des papillomavirus humains (HPV) en dépistage primaire des lésions précancéreuses et cancéreuses du col de l’utérus et de la place du double immuno-marquage p16/Ki67
Recommandatons Haute Autorité de Santé (HAS juillet 2019)
A last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: a modelling study
Lancet Oncol 2018 Dec;19(12):1569-1578 | doi: 10.1016/S1470-2045(18)30536-9. Epub 2018 Nov 1.
Dépistage du col de l'utérus : la France à la traîne
GENESIS - N° 199 - Novembre 2018
Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses
BMJ018 Dec 5;363:k4823 | doi: 10.1136/bmj.k4823
Dépistage du cancer du col utérin : un tournant ?
GYNÉCOLOGIE OBSTÉTRIQUE PRATIQUE 8 N° 293 • Mars 2017
Dépistage organisé du cancer du col en France
GENESIS - N° 192 - Novembre/Décembre 2016
Nouvelles orientations pour le triage des HPV positifs dans le dépistage du cancer du col utérin, un regard international
GENESIS - N° 192 - Novembre/Décembre 2016
Effect of VIA Screening by Primary Health Workers: Randomized Controlled Study in Mumbai, India
J Natl Cancer Inst. 2014 Mar;106(3) | DOI: 10.1093/jnci/dju009
Test HPV et dépistage du cancer du col
Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: systematic review and meta-analysis
International Journal of Cancer | doi: 10.1002/ijc.33035 (May 4,2020)
Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening
British Journal of Cancer (April 3, 2020)
Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening
International Journal of Cancer | DOI: 10.1002/ijc.32973 (March 14, 2020)
Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening
International Journal of Cancer | DOI: 10.1002/ijc.32973, (March 1, 2020)
A Systematic Review of Tests for Postcolposcopy and Posttreatment Surveillance
Journal of Lower Genital Tract Disease Volume 24, Number April 2, 2020
2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for Risk Estimation, Recommended Management, and Validation
Journal of Lower Genital Tract Disease Volume 24, Number April 2, 2020
A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines
Journal of Lower Genital Tract Disease Volume 24, Number April 2, 2020
Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months
JAMA. 2018;320(1):43-52. doi:10.1001/jama.2018.7464
Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer
Ann Intern Med 2018 Jan 2;168(1):20-29 | doi: 10.7326/M17-1609
Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands
BMJ 2016;355:i4924 | doi: 10.1136/BMJ.i4924
Le dépistage primaire par test HPV offre une plus grande protection (60-70%) contre le cancer invasif du col que le dépistage par frottis
The Lancet, 2014 ;383, 9916, 524 - 532
Le test HPV dans le dépistage du cancer du col utérin réduit de 70% le cancer invasif comparé au frottis
The Lancet, Vol. 383, No. 9916, p524–532 Published: November 3, 2013
HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study
The BMJ | BMJ 2010;340 | doi : 10.1136/BMJ.c1040
Vaccination HPV
HPV Vaccination and the Risk of Invasive Cervical Cancer
The New England Journal of Medicine 383;14 nejm.org October 1, 2020
Design and content validation of a survey questionnaire assessing the determinants of human papillomavirus (HPV) vaccine hesitancy in France: A reactive Delphi study
Elsevier Vaccine. 2020 Jul 25;S0264-410X(20)30943-9 | doi: 10.1016/j.vaccine.2020.07.027.
Vaccination HPV universelle, garçons et filles
Recommandations Haute Autorité de Santé (HAS décembre 2019)
Pour un dépistage et une vaccination unvierselle contre la papillomavirus
Appel des 50 : Académies, Collèges, Socités et Syndicaux médicaux
Communiqué de presse 20 mars 2019
Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancerin 181 countries, 2020-99 : a modelling study
- Published online February 19, 2019
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15–26 Years of Age
2018 by the American College of Obstetricians and Gynecologists
Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017±2035: Example from Australia
PLOS ONE | February 14, 2018
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
- Published online September 5, 2017
Nine-valent human papillomavirus vaccine: great science, but will it save lives?
- Published online September 5, 2017
Vaccination contre les infections à HPV et risque de maladies autoimmunes : une étude Cnamts/ANSM rassurante - Point d'information
ANSM/CNAMTS (13/09/2015)
Vaccins anti-HPV et risque de maladies autoimmunes : étude pharmacoépidémiologique
ANSM/CNAMTS (Rapport final, septembre 2015)
No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England
Vaccine (2017) 1729-1732 - Copyright 2017 Published by Elsevier Ltd.
Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs
Journal of Infectious Diseases Advance Access published (July 30, 2015)
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
The New England Journal of Medicine 372;8 nejm.org (February 19, 2015)
Safety of human papillomavirus vaccines: a review
Expert Opin. Drug Saf. (2015) 14(5) (February 24, 2015)
Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other Demyelinating Diseases of the Central Nervous System
JAMA. 2015;313(1):54-61 | doi:10.1001/jama.2014.16946 (January 6, 2015)
Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia
BMJ 2014;348:g1458 doi: 10.1136/bmj.g1458 (March 4,2014)
Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
JAMA January 6, 2015 Volume 313, Number 1
Safety of human papillomavirus vaccines: a review
Expert Opin. Drug Saf. (2015) 14(5)
HPV “Coverage”
N. Engl J Med 372;8 nejm.org february 19, 2015
The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon
BMJ 2014;348:g1458 doi: 10.1136/Expert Rev. Vaccines Early online, 1–12 (2014)
Avis d’experts (Europe et Australie)
Décembre 2013
Profil de sécurité des vaccins HPV, faut-il s'en inquiéter ?
Génésis - N°177 Février/mars 2014
Safety of Human Papillomavirus Vaccines: A Review
Springer International Publishing Switzerland 2013
Vaccins HPV : que font nos autorités de santé face à la crise ?
(12 décembre 2013, Le Quotidien du Médecin)
Prévention du cancer du col utérin (II) : vaccination HPV prophylactique, connaissances actuelles, modalités pratiques et nouveaux enjeux
Presse Med. 007; 36: 640 - 2007 Elsevier Masson
Prévention du cancer du col utérin (I) : apport du dépistage, récents progrès et perspectives
Presse Med. 2007; 36: 92-111 - 2006 Elsevier Masson
HPV & cancer de la gorge
Understanding personal risk of oropharyngeal cancer: risk-groups for oncogenic oral HPV infection and oropharyngeal cancer
(Annals of Oncology 00: 1–5, 2017)
Cunnilingus et cancer de la gorge : Michael Douglas dit vrai, mais pas d'inquiétude
(4 juin 2013, Le Nouvel Observateur)
Que penser du lien établi par Michael Douglas entre sexe oral et cancer de la gorge : l’avis du spécialiste français du papillomavirus - Atlantico
Que penser du lien établi par Michael Douglas entre sexe oral et cancer de la gorge : l’avis du spécialiste français du papillomavirus - Atlantico
Transmission HPV
Lancet Infect Dis2019 Mar;19(3):317-326 | doi: 10.1016/S1473-3099(18)30655-8. Epub 2019 Feb 10
Hand-to-genital and genital-to-genital transmission of human papillomavirus between male and female sexual partners (HITCH): a prospective cohort study
Recherche et développement
HPV en gynécologie, nouvelles pratiques en marche
GENESIS - N° 204 - Décembre 2020
Infection à HPV, 25 années de recherche
GENESIS - N° 192 - Novembre/Décembre 2016